Results 11 to 20 of about 853 (171)

Antagonism of the Azoles to Olorofim and Cross-Resistance Are Governed by Linked Transcriptional Networks in Aspergillus fumigatus [PDF]

mBio, 2022
Aspergillosis, in its various manifestations, is a major cause of morbidity and mortality. Very few classes of antifungal drugs have been approved for clinical use to treat these diseases and resistance to the first-line therapeutic class, the triazoles ...
Norman van Rhijn, Sam Hemmings, Isabelle S. R. Storer, Clara Valero, Hajer Bin Shuraym, Gustavo H. Goldman, Fabio Gsaller, Jorge Amich, Michael J. Bromley   +8 more
doaj   +10 more sources

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim [PDF]

Journal of Antimicrobial Chemotherapy, 2020
OBJECTIVES: Eumycetoma is currently treated with a combination of itraconazole therapy and surgery, with limited success. Recently, olorofim, the lead candidate of the orotomides, a novel class of antifungal agents, entered a Phase II trial for the ...
Birch, M. (Mike), Eadie, K. (Kimberley), Fahal, A.H. (Ahmed), Konings, M. (Mickey), Lim, W. (Wilson), Oliver, J.D. (Jason D.), Rijnders, B.J.A. (Bart), Sande, W.W.J. (Wendy) van de, Verbon, A. (Annelies)   +8 more
core   +5 more sources

Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance [PDF]

Emerging Microbes and Infections, 2022
Olorofim (F901318) is a new antifungal currently under clinical development that shows both in vitro and in vivo activity against a number of filamentous fungi including Aspergillus fumigatus. In this study we screened A. fumigatus isolates for intrinsic
Jochem B. Buil, Jason D. Oliver, Derek Law, Tim Baltussen, Jan Zoll, Margriet W.J. Hokken, Marlou Tehupeiory-Kooreman, Willem J.G. Melchers, Mike Birch, Paul E. Verweij   +9 more
doaj   +5 more sources

Refractory Microascus Bronchopulmonary Infection Treated with Olorofim, France

Emerging Infectious Diseases, 2023
We report 3 cases of successful treatment of Microascus spp. bronchopulmonary infection in a multiple-traumatized patient and 2 lung transplant recipients in France.
Emmanuel Faure, Olivier Brugière, Sylvie Colin de Verdiere, Fanny Vuotto, Lucie Limousin, Emilie Cardot, Camille Cordier, Pauline Coulon, Dea Garcia-Hermoso, Olivier Lortholary, Fanny Lanternier   +10 more
doaj   +3 more sources

Review of the Novel Investigational Antifungal Olorofim [PDF]

Journal of Fungi, 2020
The incidence of invasive fungal infections caused by molds and endemic fungi is increasing. There is also concern regarding increased rates of reduced susceptibility or frank resistance among Aspergillus and Coccidioides species, while Scedosporium ...
Nathan P. Wiederhold
doaj   +3 more sources

Correction: Review of the novel antifungal drug olorofim (F901318) [PDF]

BMC Infectious Diseases
Yuri Vanbiervliet, Tine Van Nieuwenhuyse, Robina Aerts, Katrien Lagrou, Isabel Spriet, Johan Maertens   +5 more
doaj   +3 more sources

In Vitro Activity of the Novel Antifungal Olorofim against Scedosporium and Lomentospora prolificans

Microbiology Spectrum, 2023
Scedosporium spp. and Lomentospora prolificans are an emerging group of fungi refractory to current antifungal treatments. These species largely affect immunocompromised individuals but can also be lung colonizers in cystic fibrosis patients.
Ourania Georgacopoulos, Natalie Nunnally, Derek Law, Mike Birch, Elizabeth L. Berkow, Shawn R. Lockhart   +5 more
doaj   +3 more sources

Screening of Pandemic Response Box Library Reveals the High Activity of Olorofim against Pathogenic Sporothrix Species

Journal of Fungi, 2022
The increase in the prevalence and severity of fungal infections and the resistance to available antifungals highlights the imperative need for novel therapeutics and the search for new targets.
Luana Pereira Borba-Santos, Rodrigo Rollin-Pinheiro, Yasmin da Silva Fontes, Giulia Maria Pires dos Santos, Glauber Ribeiro de Sousa Araújo, Anderson Messias Rodrigues, Allan J. Guimarães, Wanderley de Souza, Susana Frases, Antonio Ferreira-Pereira, Eliana Barreto-Bergter, Sonia Rozental   +11 more
doaj   +3 more sources

Olorofim demonstrates <i>in vitro</i> activity against <i>Coccidioides</i> species, including isolates against which fluconazole has reduced activity. [PDF]

Antimicrob Agents Chemother
We evaluated the in vitro activity of olorofim against Coccidioides species. Olorofim demonstrated potent in vitro activity against all isolates tested with a minimum inhibitory concentration (MIC) range ≤0.008-0.06 µg/mL and geometric mean MIC of 0.010 ...
Wiederhold NP, Patterson HP, Ferrer D, Garcia V, Thompson GR, Patterson TF.   +5 more
europepmc   +7 more sources

Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth

Microbiology Spectrum
Olorofim, the first member of the novel class of antifungal drugs, the orotomides, shows promising anti-Aspergillus activity and is currently in phase III clinical development.
Alexander Kühbacher, Mike Birch, Jason D. Oliver, Fabio Gsaller   +3 more
doaj   +3 more sources